CapitalBio® BioelectronSeq 4000 System (abbreviation: BES 4000) is a next-generation sequencing system developed and produced by the cooperation between CapitalBio Corporation and Thermo Fisher Scientific Inc. in China. The system using semiconductor sequencing technology, combined with clinical testing kits and automated data analysis & management software, is suitable to be deployed and placed in clinical diagnostic laboratories. BES 4000 system has obtained CFDA Medical Device Registration Certifiate (Medical Device Registration Certifiate No.: National Instrument Registration Permit 20153400309) in Feb. 2015.
Based on the innovative semiconductor sequencing technology with natural biochemistry to directly translate chemical information (pH) into digital data (DNA sequences) through real-time detection on hydrogen ion released as a byproduct when a nucleotide is incorporated into a strand of DNA by a polymerase.
Choosing different types of chip, producing 10~60 Gb data per run, very suitable for clinical diagnostic laboratories to conduct clinical testing independently.
Fast Sequencing
Sequencing workflow with run-times of 2–4 hours and two runs per day, enabling the clinical experimenters to take advantage of the daily working hours, improving work effectiveness.
Long Reads
Enabling read length up to 200 bases and capable for sequencing the whole length of plasma cell-free DNA
High Scalability
Choosing different types of sequencing chip to complete applications of different read length and data throughput, without any changes in the hardware.
Friendly Operation Interface
Friendly interface, simple operation and proficiently using after one-day training.